NYC Reports First Case of Severe Mpox Strain

New York City confirmed its first case of the more dangerous clade I mpox virus on March 13, 2026 — a travel-related infection in a person who recently visited Europe [1][2]. The diagnosis, the twelfth clade I case detected in the United States since November 2024, arrives amid an accelerating global spread of the strain that has killed hundreds in Central Africa, triggered local transmission chains in Western Europe, and prompted the World Health Organization to issue standing emergency recommendations through August 2026 [3][4].

While city officials stressed that the risk to New Yorkers remains low, the case exposes a converging set of public health threats: the steady geographic expansion of a virus with a fatality rate several times higher than the strain that swept the globe in 2022, a vaccination campaign that has barely reached the most at-risk populations, and the recent emergence of a recombinant mpox variant that existing diagnostic tests may miss entirely.

The NYC Case: What We Know

The New York City Health Department announced on March 13 that it had identified clade I mpox in a resident who recently traveled to Europe [1]. Confirmatory testing was performed by the Centers for Disease Control and Prevention. The individual has been recovering well and is isolating until symptoms have resolved [2].

"There is no known local transmission of mpox clade I in New York City and the risk remains low for New Yorkers," said NYC Health Commissioner Dr. Alister Martin [1][2].

No additional clade I cases have been identified in the five boroughs. The city reported 398 clade II mpox cases in 2025 and 45 through March 10, 2026 — all of the milder strain that circulated during the 2022 global outbreak [2]. The detection of a clade I case linked to European travel, rather than direct travel from Africa, reflects how the virus has established new footholds far from its origin in the Democratic Republic of the Congo.

Why Clade I Matters: The Severity Gap

Mpox virus exists in two major genetic groups. Clade II, the strain behind the 2022 global outbreak that produced roughly 4,000 cases in New York City alone, carries a case fatality rate below 1% in most modern clinical settings [5][6]. Clade I is a fundamentally different threat.

Historical data compiled in a systematic review published in The Lancet Infectious Diseases found clade I had a case fatality rate of approximately 10.6%, compared to 3.6% for clade II [7]. While those figures reflect outbreaks in settings with limited healthcare infrastructure and high rates of pediatric and immunocompromised patients, the more recent clade Ib strain driving the current epidemic in Central and Eastern Africa has maintained a fatality rate of 3–4% — still significantly higher than clade II [5].

The clinical picture also differs. Clade Ib tends to produce lesions predominantly on the genitals, making diagnosis more difficult compared to the chest, hand, and foot lesions typical of earlier outbreaks [5]. Severe complications are most common in individuals with weakened immune systems, children, and pregnant women [8].

Critically, the antiviral drug tecovirimat — once considered a potential treatment option — did not shorten the duration of mpox lesions in a clinical trial conducted in the Democratic Republic of the Congo, leaving high-quality supportive care as the primary intervention [5][8].

The African Epicenter: 46,000 Cases and Counting

The current clade I epidemic traces back to South Kivu province in the Democratic Republic of the Congo, where clade Ib emerged at least as early as September 2023 [3][4]. The outbreak has since grown to more than 46,000 confirmed cases across Central and Eastern Africa, with community transmission documented in at least eleven countries: Burundi, the DRC, Kenya, Malawi, Mozambique, Republic of Congo, Rwanda, South Africa, Tanzania, Uganda, and Zambia [3].

The DRC has borne the overwhelming burden, with over 800 fatalities recorded as the epidemic surpassed 29,000 cases by September 2024 alone [4]. The scale of the crisis prompted the WHO to declare a public health emergency of international concern and issue standing recommendations that remain in effect through August 2026 [3].

Source: European Centre for Disease Prevention and Control

Data as of Jan 15, 2026CSV

From Africa to Europe to America: The Expanding Transmission Chain

What distinguishes the current moment from earlier phases of the outbreak is the emergence of local, sustained transmission of clade Ib in Western Europe — transmission that no longer requires a direct travel link to Africa.

Spain reported its first locally acquired clade Ib case on October 10, 2025, followed by the Netherlands on October 17 [9]. Italy and Portugal soon confirmed additional cases. By January 2026, the European Centre for Disease Prevention and Control documented 73 clade I cases in a single month across the EU/EEA — up from just 8 cases in September 2025 [9][10].

The majority of European cases with available epidemiological data have no documented travel history to a clade Ib-affected country, indicating established person-to-person transmission chains within sexual networks of men who have sex with men [9][10].

This European transmission corridor is directly relevant to the NYC case. Unlike earlier U.S. clade I detections, which were linked to travel from Central and Eastern Africa, the New York patient contracted the virus in Europe — evidence that the virus has leapfrogged its original geographic boundaries and established intermediate transmission hubs that increase the risk of further global seeding [1][2].

The U.S. Picture: Twelve Cases, a Pattern Forming

Since November 2024, the United States has now confirmed twelve clade I mpox cases [2][11]. The first was detected in California in a traveler returning from East Africa. Additional travel-associated cases followed in Georgia, New Hampshire, and New York State [11][12].

But the most concerning development came in October 2025, when three unrelated individuals in Southern California — in Long Beach and Los Angeles — tested positive for clade Ib with no history of recent international travel [12][13]. Genomic analysis linked these cases to an earlier U.S. case from August 2025, suggesting limited domestic transmission chains had formed, primarily within communities of gay and bisexual men [13].

The CDC has stated it expects additional clade Ib cases in the United States, following the pattern observed in Western Europe [11].

Source: GDELT Project

Data as of Mar 15, 2026CSV

A Hybrid Threat: The Recombinant Strain

Adding another layer of complexity, the WHO reported in February 2026 that a recombinant mpox virus — containing genomic elements from both clade Ib and clade IIb — had been identified in two patients: one in the United Kingdom (detected December 2025) and one in India (detected September 2025) [14][15].

The recombinant virus results from a natural process in which two mpox strains infect the same individual simultaneously and exchange segments of their genomes. Both patients had recent travel histories and experienced mild illness, with no secondary cases detected through contact tracing [14][15].

While the WHO stressed it is premature to draw conclusions about the transmissibility or severity of the recombinant strain, the agency issued a pointed warning: standard clade differentiation PCR tests "may not reliably identify recombinant MPXV strains," meaning genomic sequencing is essential for detection [14]. In a world where most jurisdictions rely on PCR alone, recombinant variants could circulate undetected.

The Vaccination Gap

The primary defense against mpox remains the JYNNEOS vaccine, a two-dose series that became commercially available in the U.S. in April 2024 [16]. The Biomedical Advanced Research and Development Authority has secured $143.6 million in contracts with Bavarian Nordic for a freeze-dried formulation with improved shelf life, with manufacturing beginning in 2026 [16].

Yet the vaccination campaign faces a stark arithmetic problem. The CDC estimates approximately 2 million at-risk individuals are eligible for mpox vaccination in the United States — and most remain unvaccinated or only partially vaccinated [16][17].

The NYC Health Department is urging at-risk populations to complete the two-dose JYNNEOS series, specifically targeting men who have sex with men, transgender, nonbinary, and gender non-conforming individuals, those planning travel to areas with clade I spread, and anyone who has had close contact with a suspected mpox case within 14 days of exposure [1][2]. Vaccination sites are available through the NYC Health Map or by calling 311.

What Comes Next

The trajectory of clade I mpox in the United States depends on several variables that remain uncertain: whether local transmission chains establish themselves beyond the California cluster, whether the recombinant strain proves to have altered characteristics, and whether vaccination rates among at-risk populations improve before the virus gains a wider foothold.

The European experience offers a cautionary template. In the span of five months — from October 2025 to early 2026 — clade Ib went from zero locally acquired cases in the EU to dozens per month, spreading through sexual networks across at least four countries [9][10]. The virus exploited the same vulnerability it found in 2022: insufficient vaccination coverage in the populations most at risk.

New York City's experience during the 2022 clade II outbreak, when 4,000 cases overwhelmed sexual health clinics and vaccine supply, demonstrated both the speed at which mpox can spread in dense urban sexual networks and the effectiveness of a mobilized public health response [2]. The question now is whether the city — and the country — can mount a proportionate response to a more dangerous strain before local transmission takes hold, rather than after.

The risk to the general public remains low. But for the specific communities most affected by mpox, the arrival of clade I on American shores is not a theoretical concern. It is the twelfth data point in a pattern that has only moved in one direction.